Exscientia plc
http://www.exscientia.co.uk
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Exscientia plc
AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns
All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Allcyte GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice